Wisconsin Alumni Research Foundation

Wisconsin Alumni Research Foundation. Established in 1925, it is one of the oldest and most successful university-based technology transfer organizations in the world. Founded by University of Wisconsin–Madison biochemist Harry Steenbock, its creation was spurred by his desire to ensure his invention for enriching foods with vitamin D would benefit the public. The organization manages the intellectual property arising from research at the University of Wisconsin–Madison, securing patents and licensing innovations to industry to generate revenue that is reinvested into the university's research enterprise.

History

The foundation was incorporated in 1925 following Harry Steenbock's development of a process using ultraviolet light to increase the vitamin D content in foods like milk. Concerned about commercial exploitation, Steenbock assigned his patent to the newly formed alumni foundation. Its first major success was licensing the vitamin D process to Quaker Oats for use in its product Pablum. This early model of patenting and licensing academic research for the public good set a national precedent. Throughout the 20th century, it played a critical role in funding groundbreaking work at the University of Wisconsin–Madison, including support for the research of Har Gobind Khorana, who won the Nobel Prize in Physiology or Medicine in 1968 for interpreting the genetic code. Landmark legal battles, such as defending the patent for the anticoagulant warfarin, solidified its reputation for robust intellectual property management.

Governance and operations

The organization is governed by a board of directors primarily composed of University of Wisconsin–Madison alumni and university representatives, ensuring alignment with the institution's academic mission. Day-to-day operations are led by a professional staff, including a chief executive officer, currently Erik Iverson. Its core functions involve evaluating invention disclosures from university researchers, filing for patent protection through the United States Patent and Trademark Office, and negotiating licensing agreements with companies ranging from startups to multinational corporations like Merck & Co. and Monsanto. A portion of the licensing revenue is shared with the inventor and their academic department, while the majority flows into a growing endowment to fund future research.

Technology transfer and commercialization

The foundation operates a comprehensive technology transfer process, working closely with faculty, staff, and students at the University of Wisconsin–Madison. Its staff of licensing managers and patent attorneys assess the commercial potential of hundreds of new inventions reported annually. It actively markets technologies to industry partners and facilitates the creation of spin-off companies, such as the biotechnology firm Promega. The organization also manages the University of Wisconsin–Madison's copyright and trademark portfolio. Beyond licensing, it provides funding through programs like the WARF Accelerator Program to help advance early-stage discoveries toward commercialization.

Notable inventions and discoveries

The foundation's portfolio includes numerous transformative innovations that have emerged from the University of Wisconsin–Madison. Among the most famous is the blood-thinning medication warfarin, originally developed as a rodenticide, which became a globally essential pharmaceutical. Key contributions to computer science include the invention of the WISC computer architecture and foundational work on dynamic random-access memory (DRAM). In the life sciences, it has managed patents for the first method to synthesize cortisone, the cancer drug Velcade (bortezomib), and the revolutionary gene-editing technology known as CRISPR-Cas9, based on the pioneering research of Jennifer Doudna and Emmanuelle Charpentier. Other significant inventions range from the bone density scan technology used in dual-energy X-ray absorptiometry to the consumer product Buckyballs.

Financial impact and endowment

The financial success of the foundation has had a profound impact on the University of Wisconsin–Madison. Since its inception, it has returned over $3 billion in royalty income to support research, faculty, and facilities. Its endowment, valued at approximately $4.3 billion as of 2023, is among the largest of any public university in the United States. This endowment provides a stable, perpetual source of funding, distributing over $100 million annually to the university. These funds are allocated through the WARF Professorships program, graduate fellowships, and direct grants for research equipment and projects, insulating the university's research mission from fluctuations in state funding and federal grants from agencies like the National Institutes of Health.

Category:Technology transfer organizations Category:University of Wisconsin–Madison Category:Organizations based in Madison, Wisconsin Category:1925 establishments in Wisconsin